NRG Oncology Semiannual Meeting - Pre-register today to have your fee waived!
We hope you can join us for the NRG Oncology Semiannual Meeting, January 9-11, 2020, at the Marriott Marquis Houston in Houston, TX. Pre-Registration for this meeting is complimentary for all NRG members who pre-register by the deadline of December 19, 2019. We kindly ask that everyone please pre-register for this meeting before the deadline. Onsite registration will incur a $100 fee. Please note that the fee for the Winter Symposium will not be waived.
Important Information:The meeting schedule has significantchanges from past meetings. Please review the preliminary agenda carefully.
All Registrants: This is a new registration system and will require you to select the button under “NEW ACCOUNT PROFILE” to establish an account for the first time.
OTHER PROTOCOL NOTICES
CCTG CE.7: A new CCTG CE.7 Newsletter is available on the CTSU website. The Newsletter provides a status update for the trial, along with some reminder information for RTQA processes required with the recently approved Amendment 1 trial modification. It also notes that a webinar to promote the CE.7 trial and provide some refresher training will be planned in the last quarter of this year.
NRG-GY004: Notification of Signature Requirement memo (posted on CTSU)
NRG-GY004: Preparation for Upcoming Database Lock and Analysis memo (posted on CTSU)
NRG-GY009: Block Submission Reminder memo (posted on CTSU)
NRG-GY018: MMR and PD-L1 Kit Ordering (memo posted on CTSU)
Form TR for Biospecimens Shipped to NRG Biospecimen Bank-Columbus Read more
Biospecimen Bank-Columbus & SDMC Undergoing Refurbishment Read more
3. VTOC TRAINING
The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, November 13.
DRUG SAFETY UPDATES
Safety updates have been issued for the following studies:
WEBSITE FOR SAFETY REPORTS
CRA and CTN MENTORSHIP PROGRAM
Are you a new CRA or CTN within NRG Oncology? Would you like a mentor to help guide you through your new role as a CRA or CTN? Are you an institution in need of more guidance after an audit? The Mentorship Working Group can provide you a mentor! Apply by visiting http://www.nrgoncology.org -- Nurses & CRAS tab -- Mentorship Program.
You will find the Mentor Request Form to complete. The instructions on how to submit are located on the form. Hope to hear from you soon!
Do you need general information to help you get started in NRG Oncology? The NRG Oncology Mentorship Working Group would like to remind you of a valuable resource. The “Introductory Materials” for CRAs and CTNs is available on the Mentorship Program page of the NRG Oncology website. This online resource was designed to make the introduction to NRG Oncology as smooth as possible by providing information regarding specific processes and contacts to be used when conducting NRG Oncology clinical trials. The information is intended to assist new members in understanding how NRG Oncology trials operate and who to contact when there are questions or difficulties.
Call for Research Proposals
The NRG Oncology Colorectal Cancer subcommittee is seeking vendors and researchers with ctDNA expertise in the field. An RFA for the randomized phase II/III colorectal prospective clinical trial, NRG-CR1902 is posted here. We are seeking a biomarker assay partner to perform CLIA-certified assay testing of patients to detect ctDNA from plasma samples at the time of enrollment and at end of completion of planned adjuvant therapy. Responses to the RFA are due no later than Friday, November 1, 2019. Please direct responses and any questions to Chet Cornman at email@example.com.
Health Disparities Committee Accepting Applications for Membership
The NRG Oncology Health Disparities Committee is accepting applications for membership. Applicants will need to submit:
A one (1) page maximum cover letter stating the reasons why the applicant wishes to join the committee, contributions the applicant will make to the group, and outline of relevant past contributions and accomplishments.
Applicants may use the new NIH biosketch format in lieu of a cover letter.
If you are interested in becoming a member of the Health Disparities Committee, please complete the application and return the form and necessary materials by Friday, November 22, 2019 to Committee-Nominations@nrgoncology.org. Click here to download the committee information/applicant requirements and the application.
NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.
Chumsri S, Li Z, Serie DJ, Mashadi-Hossein A, Colon-Otero G, Song N, Pogue-Geile KL, Gavin PG, Paik S, Moreno-Aspitia A, Perez EA, Thompson EA. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. J Clin Oncol. 2019 Oct 17:JCO1900443. doi: 10.1200/JCO.19.00443. [Epub ahead of print] PubMed PMID: 31622131. Read More
de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, Ballman K, Aspitia AM, Zardavas D, Roca L, Gelber RD, Piccart-Gebhart M, Suter T. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Res Treat. 2019 Oct 11. doi: 10.1007/s10549-019-05453-z. [Epub ahead of print] PubMed PMID: 31605311. Read More
Swain SM, Tang G, Lucas PC, Robidoux A, Goerlitz D, Harris BT, Bandos H, Geyer CE Jr, Rastogi P, Mamounas EP, Wolmark N. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination. Breast Cancer Res Treat. 2019 Nov;178(2):389-399. doi: 10.1007/s10549-019-05398-3. Epub 2019 Aug 19. PubMed PMID: 31428908. Read More
Wade KNS, Brady MF, Thai T, Wang Y, Zheng B, Salani R, Tewari KS, Gray HJ, Bakkum-Gamez JN, Burger RA, Moore KN, Bookman MA. Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. Gynecol Oncol. 2019 Oct;155(1):69-74. doi: 10.1016/j.ygyno. 2019.07.020. Epub 2019 Aug 10. PubMed PMID: 31409486. Read More
Please note the following upcoming meeting and abstract submission deadline dates